key: cord-0972364-2fo1fn8q
authors: Schulte, Eva C.; Hauer, Larissa; Kunz, Alexander B.; Sellner, Johann
title: Systematic Review of Cases of Acute Myelitis in Individuals with COVID‐19
date: 2021-06-01
journal: Eur J Neurol
DOI: 10.1111/ene.14952
sha: c27119760fdd68ee4bfae8c494ec3ef6c587e95b
doc_id: 972364
cord_uid: 2fo1fn8q

BACKGROUND: An incremental number of cases of acute transverse myelitis (ATM) in individuals with ongoing or recent coronavirus disease 2019 (COVID‐19) have been reported. METHODS: We performed a systematic review of cases of ATM described in the context of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection by screening both articles published and in preprint. RESULTS: Twenty cases were identified. There was a slight male predominance (60.0%) and the median age was 56 years. Neurological symptoms first manifested after a mean of 10.3 days from the first onset of classical, mostly respiratory symptoms of COVID‐19. Overall, COVID‐19 severity was relatively mild. PCR of CSF for SARS‐CoV‐2 was negative in all 14 cases examined. Cerebrospinal fluid findings reflected an inflammatory process in most instances (77.8%). Aquaporin‐4 and myelin oligodendrocyte protein (tested in 10 and 9 cases, respectively) antibodies in serum were negative. On MRI, the spinal cord lesions spanned a mean of 9.8 vertebral segments, necrotic‐hemorrhagic transformation was present in three cases and two individuals had additional acute motor axonal neuropathy. More than half of the patients received a second immunotherapy regimen. Over a limited follow‐up period of several weeks, 90% of individuals recovered either partially or near fully. CONCLUSION: Although causality cannot readily be inferred, it is possible that cases of ATM occur para‐ or post‐infectiously in COVID‐19. All identified reports are anecdotal and case descriptions are heterogenous. Whether the condition and the observed radiological characteristics are specific to SARS‐CoV‐2 infection needs to be clarified.

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is beginning to provide further insights to infection-related neurological manifestations (1) . The conditions reported in the context of the coronavirus disease 2019 (COVID-19) include but are not limited to encephalitis, myelitis, meningitis, acute disseminating encephalomyelitis (ADEM), metabolic and acute hemorrhagic necrotizing encephalopathy, cerebrovascular diseases, Guillain-Barre syndrome (GBS), cranial polyneuritis, dysautonomia, and myopathies (2) . From a pathogenetic viewpoint, neurologic manifestations can fall into any of four categories-direct virus effects on the nervous system, para-or post-infectious immune-mediated diseases and neurologic conditions stemming from complications of systemic COVID-19 (3) .

Reports of neurological manifestations in observational cohorts vary widely from 3.5% to 84% (4) . One large prospective study of 4491 individuals with COVID-19 in New York City (USA) reported neurologic complications in 606 of them (13.5%) (4) . In that study, encephalopathy, seizures, and stroke were the most common manifestations. At the same time, one of the earliest studies from Wuhan also considered mild and unspecific neurologic symptoms like anosmia, headache, and dizziness and found that 78 out of 241 individuals (36.4%) with COVID- 19 were affected (5) .

Neither one of the above cohort studies depicted cases of myelitis in the context of COVID-19.

Yet, there is mounting-though, at this point, largely anecdotal-evidence of individuals with acute transverse myelitis (ATM) and a history of infection with SARS-CoV-2. Considering more than 50 million cases of COVID-19 have been recorded worldwide to date and that this number will only grow, even rare complications may be important to recognize, especially if they require specific management strategies. Eight cases of acute and subacute neurologic complications in the form of encephalitis, seizures, leukencephalopathy, neuropathy or myopathy due to direct viral invasion have been reported for SARS-CoV-1 and Middle Eastern Respiratory Syndrome (MERS)-CoV (6) (7) (8) . Yet, no reports of ATM associated with these two beta-coronaviruses, which

This article is protected by copyright. All rights reserved caused epidemics in the recent history, are found in the literature (9) . However, the total number of infected individuals for both viruses combined only totaled to approximately 11,000 individuals; the frequency may not have been sufficient to notice potentially rarer complications (3) . For CoV-OC43 or CoV-229E, which belong to another subspecies of coronaviruses, cases of severe central nervous system (CNS) manifestations including encephalitis, ADEM or GBS in combination with detection of the virus by histological analysis of brain section have been reported (10, 11 ). There has also been a case of acute flaccid myelitis in association with respiratory CoV-OC43 and CoV-229E co-infection (12) .

In order to elucidate a potential occurrence of ATM in association with SARS-CoV-2 infections, we systematically reviewed all cases reported to date.

This systematic review was carried out in accordance with PRISMA guidelines (13) . We searched Medline and two preprint servers (MedRxiv and BioRxiv) from database inception to October 20th, 2020, using the following search terms "myelitis", "myelopathy", "spinal cord", "neurologic manifestations", "neurological manifestations" as well as "neurology" in combination with "SARS-CoV-2" and "COVID-19". No language restrictions were applied. All types of studies were considered but only studies presenting original data were included in downstream analyses.

Additionally, reference lists of included articles were also followed up to check for additional relevant studies that might have been missed.

Study bias was assessed using the Newcastle-Ottawa scale to identify possible selection bias, assessment bias, comparability issues, causality bias, and reporting bias (14) .

Cases were defined as "confirmed", "probable", or "suspected" COVID-19 cases using the case definitions put forth by the World Health Organization (WHO) and as "confirmed", "probable", or "possible" SARS-CoV-2 myelitis as described previously (3) . Confidence in SARS-CoV-2-associated myelopathy/myelitis was established using the four categories ("suspected myelopathy", "myelopathy", "possible myelitis", and "myelitis") suggested by Ellul et al.(3) . Overall COVID-19 severity was judged using the 0 to 10 scale of the WHO outcome criteria (15). Wherever timeframes of disease course were not stated explicitly, we employed, where possible, a "best Accepted Article obesity (2/18), hyperlipidemia (2/18), and hypothyroidism (2/18). Among the rarer comorbidities were HIV (1/18) and glucose-6-phosphate-dehydrogenase deficiency (1/18) . Six out of 18 individuals did not have comorbidities (Table 1) .

In most instances, neurological symptoms consisted of the classical triad of weakness of the lower extremities, sensory deficits in the form of a sensory level, and bladder or bowel dysfunction. Details on the neurological presentation and individual findings are presented in Tables 1 and 2 Table 1 ). Only in the instance of a 3-year-old child, no symptoms of respiratory tract infection or fever were reported prior to the onset of neurological symptoms (19) . COVID-19 manifestation overall was relatively mild with an average WHO score(15) of 3.21.7 (median 2, range 1 to 8), equivalent to respiratory symptoms that can be treated at home without need for hospitalization. Two cases with mild respiratory symptoms and sudden death from cardiac arrest were not included in the analysis due to the fact that the association between the COVID-19 and the deaths could not be established. Pneumonia was diagnosed in 68.4% of cases (13/19 

This article is protected by copyright. All rights reserved

Polymerase chain reaction (PCR) from nasopharyngeal swabs was performed in all cases. It was positive at some point in the disease course in 75.0% of cases (16/20 cases). In the four cases without a positive SARS-CoV-2 PCR, anti-SARS-CoV-2 antibodies were present in serum (IgG-only in 2/4; IgG/IgM in 1/4; IgG/IgM/IgA in 1/4). At the time of onset of neurological symptoms, 8/16 cases were PCR-positive. Of the 8/16 negative cases, two turned positive two or three days later, the others remained negative or where not tested again but had had a positive SARS-CoV-2 PCR prior to the onset of neurological symptoms. Chest X-rays (8/18 cases) or CTs (10/18 cases) were performed in 90.0% of individuals (18/20 cases). In five cases, these were within normal limits Table 2 ). In the majority of cases (13/15 cases), laboratory changes showed a mild, often times incomplete systemic inflammatory syndrome with slightly elevated white blood cell counts (5/14 cases), erythrocyte sedimentation rates (1/5 cases), and C-reactive protein (8/13 cases) as well as lymphocytopenia (3/11 cases). In five out of 15 cases, additional changes often seen in the context of SARS-CoV-2 infection, such as elevated d-dimer levels or liver enzymes, were also observed. In half of the cases, serological work-up for autoimmune diseases was performed. Where tested, anti-AQP4 (10/20 cases) and anti-MOG (9/20 cases) antibodies were not present and panels for systemic autoimmune diseases (9/20 cases) or anti-neuronal antibodies (3/20) returned negative results. In one individual who also had axonal motor neuropathy, anti-GD1b IgM ganglioside antibodies were detected (20) .

Cerebrospinal fluid (CSF) findings were heterogeneous but reflected some form of inflammatory process in most cases (14/18 cases): lymphocytic pleocytosis with elevated protein was seen in 6/18 cases, isolated lymphocytic pleocytosis was present in 3/18 cases and isolated protein elevation was found in 5/18 cases. CSF glucose levels were available in 11 of 18 cases and were within normal limits in nine and increased in two individuals with diabetes. If evaluated, CSFspecific oligoclonal bands were not detected (8/18) and IgG Index was unremarkable or at the Accepted Article upper limit of normal (5/18) ( Table 2 ). In all 14 cases examined, no SARS-CoV-2 RNA was detected by real-time PCR in the CSF. In two of three cases, CSF was positive for anti-SARS-CoV-2 IgG (21), in one case, it was negative (22) . No other viral or bacterial infections were detected in the CSF or serum of those 19 individuals for whom it was reported (Tables 2 and 3 for details).

Based on the WHO definitions for describing associations between SARS-CoV-2 and myelitis/myelopathy, the association was "confirmed" in two cases based on the presence of anti-SARS-CoV-2 IgG in CSF. In 40% of cases, it was "probable" (8/20 cases) with neither viral RNA or SARS-CoV-2 antibodies found in CSF but clear evidence of SARS-CoV-2 infection and no evidence of alternate causes for TM. In the remaining 50%, association was "possible" (10/20 cases) due to incomplete exclusion of potential alternate causes of TM (Tables 1 to 3) .

19 out of 20 cases had an MRI of the spinal cord, two of these (10%) were unrevealing and two showed degenerative changes, in one instance with concomitant T2 hyperintensities of the cauda. In the remaining 78.9% (15/19), classical T2 hyperintensities of the spinal cord were observed. At the time of first spinal cord imaging, lesions in nine individuals were described as non-enhancing while in three individuals they were enhancing. In the remaining cases, it is unclear whether MRIs were performed with contrast ( Table 2 ). In three instances, there was also evidence of hemorrhagic transformation and necrosis of the spinal cord lesion (19, 23, 24) .

Transverse localization was central, frequently with extension throughout most of the transverse diameter, in 7/11 cases. The thoracic subsegment of the spinal cord was affected most frequently (93.3%; 14/15 cases), followed by the cervical subsegment (53.3%; 8/15) ( Table 2) .

Interestingly, in most cases, lesions were longitudinally extensive extending over an average of 9.8  8.3 vertebral body segments (median 6; range 2 to 24) ( Table 2 ). In 93.3% of individuals with a clear lesion on spinal cord imaging, the lesion extended over three or more spinal cord segments, fulfilling the criteria for longitudinally extensive transverse myelitis (LETM). In five out of 15 individuals with a spinal cord lesion, the lesion spanned more than half the spinal cord.

Whenever performed (16/20 cases), brain MRI showed no additional supratentorial inflammatory lesions (Table 2 ). In several instances, T2 hyperintensities were described as

This article is protected by copyright. All rights reserved "patchy" (3/15) or with "patchy enhancement" (2/15), while they were continuous in the other cases (10/15).

Applying the diagnostic levels set forth by Ellul et al. specifically for myelopathy /myelitis in the context of infections with SARS-CoV-2 (3), 16/20 cases were classified as having "myelitis", three as having "possible myelitis" and one as having "myelopathy" only, due to the lack of both CSF analysis and imaging studies (Table 1) .

The majority of cases (90.0%, 18/20 cases) received some form of immune therapy. Eight of 18 cases, received either intravenous methylprednisolone (MP, seven cases) or plasma exchange (one case) alone. However, in 10 of 18 cases, more than one immune therapy was administered.

Eight individuals were treated with a combination of two different immune therapies-in most instances, intravenous methylprednisolone followed by plasma exchange-, in one case a combination of three and in another of four different immune therapies was necessary (Table 3) .

Additional antivirals or antibiotics were administered in five cases each (Table 3) . While antibiotic regimes varied, acyclovir was the most commonly used antiviral (4/5 cases). Only one of the reported individuals received an antiviral combination specifically geared at SARS-CoV-2 (ritonavir/lopinavir). Other SARS-CoV-2-specific therapies such as remdesivir, convalescent plasma, or monoclonal antibodies were not administered to any of the individuals.

Follow-up was mostly limited to several weeks of in-hospital treatment. Over this limited time period, 90.0% of individuals recovered either partially (15/20 cases) or near fully (3/20 cases).

Two patients died from sudden cardiac arrest on day five after onset of myelitis symptoms while undergoing treatment in the hospital. In one case, cardiac arrest occurred immediately following sudden-onset respiratory failure; in the other, no additional details are provided (Table 3) .

This article is protected by copyright. All rights reserved

In most of the reported cases reviewed herein, the diagnosis of myelitis in the context of SARS-CoV-2 infection was undisputed. Yet, since the majority of cases was reported as single case reports, there is likely to be reporting bias and one needs to be wary of inferring causality directly from the anecdotal data provided. Although presented as a set of cases for reasons of practicality, one needs to be wary of seeing them as a uniform cohort as they really represent single cases documented in unique individual settings. Further, interpretability is hampered by the limited number of available cases, the highly diverse patient population spanning many ages and ancestries, and the heterogeneous and, in many cases, incomplete work-up. Another possible way to assess whether SARS-CoV-2 is actually responsible for cases of TM would be to compare the incidence of myelitis cases pre-SARS-CoV-2 pandemic to the current incidence to see if there is an overall increase in cases of TM. The incidence of TM has been reported to range somewhere between 1 and 8 cases per 1 million population per year, with rates relatively stable across ancestries (27, 28). If cases that are later diagnosed as having an underlying autoimmune disorder are included, this number increased to around 32 cases per 1 million population per year (30). Extrapolated to the 107 million reported infections to date, this would mean that between 107 and 3,317 cases of TM would be expected to occur among these individuals from causes unrelated to COVID-19. Not least due to this large number and the wide

This article is protected by copyright. All rights reserved range of TM cases that can be ascribed to causes other than potentially COVID-19, it will be very important to continue to survey the situation of myelitis in COVID-19 by both systematically including neurological manifestations as outcomes in large COVID-19 cohort studies and by collecting myelitis cases in the context of COVID-19 in Neuro-COVID-19 registries (29).

A number of demographic characteristics reinforce the notion that the cases depicted herein, for the most part, truly represent myelitis caused by SARS-CoV-2 infection. First, affected individuals were of all different ages and ancestries, and had a slight predominance for males. Male have been reported to occur more frequently in men and older individuals (5) . As opposed to other neurological manifestations in the context of SARS-CoV-2 infection, overall, individuals with myelitis did not seem to have very severe respiratory COVID-19. (4, 21, 34) and that SARS-CoV-2 RNA has only very rarely been detected in the CSF or in CNS tissue, argues against this as the primary mechanism (35-37). Yet, the presence of very low viral copies in general or following degradation, as well as the examination of CSF specimen outside the peak of viral copy numbers in CSF, are potential explanations for the rare detection of SARS-CoV-2 in CSF, cannot be excluded (2) . A second possibility is indirect injury due to severe

This article is protected by copyright. All rights reserved systemic disease or cytokine storm syndrome (23, 38) . In the described cases, however, COVID- 

This article is protected by copyright. All rights reserved TM has also occurred in at least one participant in a trial for a SARS-CoV-2 vaccine developed by AstraZeneca and the University of Oxford (47). Although causality cannot be readily inferred, TM is known as a potential complication of several different vaccines and causality has shown for the oral polio vaccine and ATM (47, 48). Accordingly, with a significant portion of the world`s population going to receive a SARS-CoV-2 vaccine, post-vaccination ATM will be something to watch as vaccine trials are intensifying and vaccination efforts are starting to get underway (47).

Current estimates of neurological manifestations in COVID-19 of 7.8 to 13.5% seem high and are most likely subject to significant reporting and selection bias (4, 21) . True numbers for Accepted Article neurological sequelae may be closer to the 0.09% and 0.36% estimated for SARS-CoV-1 and

remains to be established and reports of myelitis are anecdotal, at the current scale of this global pandemic, they merit further scrutiny in a timely fashion.

This research received no funding.

Not required.

Authors have no conflict to declare.

Wong PFC, S.; Newman, P.; Makan, A. 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved neg=negative; bilat=bilateral; PE=pulmonary embolism; AID=autoimmune disease; WNL=within normal limits; + = above normal limits; ++=greatly above normal limits; -= below normal limits; (+)=upper limit of normal or slightly above normal; CRP=C-reactive protein; ESR=erythrocyte 

The international

European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection

A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details

Neurological associations of COVID-19

A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Possible central nervous system infection by SARS coronavirus

Neuromuscular disorders in severe acute respiratory syndrome

What did we learn from the previous coronavirus epidemics and what can we do better: a neuroinfectiological point of view

Coronavirus OC43 Associated with Fatal Encephalitis

Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis

A rare cause of acute flaccid paralysis: Human coronaviruses

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research

Acute necrotizing myelitis and acute motor axonal neuropathy in a COVID-19 patient

Acute transverse myelitis associated with SARS-CoV-2: A Case-Report

Acute meylitis after SARS-CoV-2 infection: a case report

Transverse Myelitis in a Child With COVID-19

A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

Acute transverse myelitis after COVID-19 pneumonia

COVID-19-associated acute necrotizing myelitis

Transverse myelitis and vaccines: a multi-analysis

Acute myelitis as a neurological complication of Covid-19: A case report and MRI findings

Post COVID-19 longitudinally extensive transverse myelitis (LETM)-a case report

COVID-19-associated acute transverse myelitis: a rare entity

Acute transverse myelitis in COVID-19 infection

Acute Transverse Myelitis Secondary to Severe

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Case Report

Transient acuteonset tetraparesis in a COVID-19 patient

Acute transverse myelitis in a HIV-positive patient with COVID-19

A Case Report of Acute Transverse Myelitis Following Novel Coronavirus Infection

Transverse myelitis related to COVID-19 infection